Phase 2 study of rituximab plusABVD in patients with newly diagnosed classical Hodgkin lymphoma

Blood

Volumn 119, Issue 18, 2012, Pages 4123-4128

  Younes, Anas ^a   Oki, Yasuhiro ^a   McLaughlin, Peter ^a   Copeland, Amanda R ^a   Goy, Andre ^a   Pro, Barbara ^a   Feng, Lei ^a   Yuan, Ying ^a   Chuang, Hubert H ^a   Macapinlac, Homer A ^a   Hagemeister, Fredrick ^a   Romaguera, Jorge ^a   Samaniego, Felipe ^a   Fanale, Michelle A ^a   Dabaja, Bouthaina Shbib ^a   Rodriguez, Maria A ^a   Dang, Nam ^a   Kwak, Larry W ^a   Neelapu, Sattva S ^a   Fayad, Luis E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; RITUXIMAB; VINBLASTINE;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; GRANULOCYTOPENIA; HODGKIN DISEASE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VOMITING;

EID: 84860712523     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-405456     Document Type: Article

References (31)

1. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478-1484.
2. Connors JM. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol. 2005;23(26):6400-6408. (Pubitemid 46222240)
3. Engert A, Diehl V, Franklin J, et al. Escalateddose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548-4554.
4. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203-212.
5. Evens AM, Hutchings M, Diehl V. Treatment of Hodgkin lymphoma: The past, present, and future. Nat Clin Pract Oncol. 2008;5(9):543-556.
6. Gordon LI, Hong F, Fisher RI, et al. A randomized phase III trial of ABVD vs. Stanford V radiation therapy in locally extensive and advanced stage Hodgkin's lymphoma: An intergroup study coordinated by the Eastern Cooperatve Oncology Group (E2496) [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21): Abstract 415.
7. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma-diagnosis and treatment. Lancet Oncol. 2004;5(1):19-26.
8. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010; 363(7):640-652.
9. Lim SH, Johnson PW. Chemotherapy: Advanced Hodgkin lymphoma-balancing toxicity and cure. Nat Rev Clin Oncol. 2011;8(11):634-636.
10. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104(12):3483-3489. (Pubitemid 39564416)
11. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040-2045.
12. Younes A. Beyond chemotherapy: New agents for targeted treatment of lymphoma. Nat Rev Clin Oncol. 2011;8(2):85-96.
13. Portlock CS, Donnelly GB, Qin J, et al. Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. Br J Haematol. 2004;125(6):701-708. (Pubitemid 38813596)
14. Rassidakis GZ, Medeiros LJ, Viviani S, et al. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: Associations with presenting features and clinical outcome. J Clin Oncol. 2002;20(5):1278-1287. (Pubitemid 34177434)
15. Schmid C, Pan L, Diss T, Isaacson PG. Expression of B-cell antigens by Hodgkin's and Reed-Sternberg cells. Am J Pathol. 1991;139(4):701-707.
16. Zukerberg LR, Collins AB, Ferry JA, Harris NL. Coexpression of CD15 and CD20 by Reed-Sternberg cells in Hodgkin's disease. Am J Pathol. 1991;139(3):475-483.
17. Rehwald U, Schulz H, Reiser M, et al. Treatment of relapsed CD20 Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: Results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood. 2003;101(2):420-424. (Pubitemid 36077558)
18. Kim S, Fridlender ZG, Dunn R, et al. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoietic murine tumor models. J Immunother. 2008;31(5):446-457.
19. Jones RJ, Lin L, Gocke C, et al. Clonotypic B cells circulate in Hodgkin's lymphoma (HL) [abstract]. Blood (ASH Annual Meeting Abstracts). 2006;108(11): Abstract 470.
20. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17(4):1244.
21. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571-578. (Pubitemid 350002965)
22. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52-59. (Pubitemid 43053523)
23. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746- 3752. (Pubitemid 47372616)
24. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol. 2003;21(4):607-614. (Pubitemid 46621893)
25. Kasamon YL, Jacene HA, Swinnen LJ, et al. Multicenter phase II study of rituximab-ABVD in classic Hodgkin lymphoma (cHL) [abstract]. J Clin Oncol. 2011;29(suppl): Abstract 8039.
26. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: Results of a phase 2 trial. Blood. 2003; 101(11):4285-4289. (Pubitemid 36857790)
27. Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003;98(2): 310-314. (Pubitemid 36828455)
28. Oki Y, Younes A. Does rituximab have a place in treating classic hodgkin lymphoma? Curr Hematol Malig Rep. 2010;5(3):135-139.
29. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21):1506-1514.
30. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-1821.
31. Younes A, Connors JM, Park SI, Hunder NNH, Ansell SM. Frontline therapy with brentuximab vedotin Combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21): Abstract 955.